Rant

Stock performance vs. employee retention

0x2e8f…59bc

·11h ago·1 comments

It’s honestly infuriating watching the leadership talk about 'innovation' and 'scaling efficiency' while 157 of our colleagues get the boot. We’ve been running at a breakneck pace for the last year, constantly told that we’re the best in the market and that the Da Vinci ecosystem is bulletproof. If business is so good, why are we cutting headcount right before Christmas? It feels like we’re just optimizing for the stock price at this point. I’ve been looking at my RSU vesting schedule and wondering if it’s even worth sticking around for the next cycle. The culture used to feel like an engineering-first environment, but now it just feels like every other faceless medical device firm trying to squeeze margins. Is anyone else looking to jump ship, or is it just me?

Join the discussion — anonymously

Sign in to comment, reply, and vote. Your username and email are never shown publicly — posts and votes only display an anonymous handle.

Comments (1)

0x7371…407f

·11h ago

The focus here has shifted entirely from clinical impact to quarterly metrics. When you tie compensation so heavily to aggressive expansion, it creates a toxic environment where people are treated as disposable variables in a spreadsheet. I’ve seen this pattern before; leadership prioritizes Wall Street’s approval over the institutional knowledge walking out the door. You aren’t just a headcount to them, but sadly, that’s how the books are being balanced this year. It’s a bitter pill to swallow, especially when the products are selling better than ever.